TY - JOUR
T1 - Alpha Globin Gene Copy Number Is Associated with Prevalent Chronic Kidney Disease and Incident End-Stage Kidney Disease among Black Americans
AU - Ruhl, A. Parker
AU - Jeffries, Neal
AU - Yang, Yu
AU - Naik, Rakhi P.
AU - Patki, Amit
AU - Pecker, Lydia H.
AU - Mott, Bryan T.
AU - Zakai, Neil A.
AU - Winkler, Cheryl A.
AU - Kopp, Jeffrey B.
AU - Lange, Leslie A.
AU - Irvin, Marguerite R.
AU - Gutierrez, Orlando M.
AU - Cushman, Mary
AU - Ackerman, Hans C.
N1 - Funding Information:
M. Cushman reports Scientific Advisor or Membership: International Society on Thrombosis and Haemostasis—journal editor, Research and Practice in Thrombosis and Haemostasis. O.M. Gutierrez discloses receiving grant funding and consulting fees from Akebia Therapeutics; grant funding and consulting fees from Amgen; grant funding from GlaxoSmithKline; consulting fees from QED Therapeutics; and Honoraria from Akebia, Amgen, Ardelyx, AstraZeneca, and Reata. J.B. Kopp reports a Patent (Vpr antibodies) with the National Institutes of Health; Scientific Advisor or Membership as a Board Member of the National Kidney Foundation serving the National Capitol Area, NIH Foundation for the Advancement of Education in the Sciences; Editorial Boards of the American Journal of Nephrology and American Journal of Physiology—Renal; and Other Interests/Relationships with the National Institute of Diabetes and Digestive and Kidney Diseases via Confidentiality disclosure agreement with Intermune, Ionis, and Third Rock; Collaboration research and development agreement with Sanofi; and Research collaboration agreement with Astra Zeneca, Gen-entech, Merck, and Third Rock. B.T. Mott reports Consultancy Agreements with Geminus Therapeutics; Ownership Interest in Geminus Therapeutics; and Patents and Inventions with Chinook Therapeutics and Geminus Therapeutics. R.P. Naik reports Consultancy Agreements with Elsevier; and Research Funding from Rigel. L.H. Pecker reports Scientific Advisor or Membership as Sickle Cell Reproductive Health Education Directive. N.A. Zakai reports Honoraria from the American Society of Hematology and the International Society on Thrombosis and Haemostasis; and Scientific Advisor or Membership via Editorial Board for Research and Practice of Thrombosis and Haemostasis, Various committees for the Hemophilia and Thrombosis Research Society, and the American Society of Hematology. All remaining authors have nothing to disclose.
Funding Information:
This is an ancillary study supported by cooperative agreement U01 NS041588 cofunded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. This research was supported in part by the Divisions of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID) (project AI001150) (A.P. Ruhl, H.C. Ackerman) and the National Heart, Lung, and Blood Institute (NHLBI) (project HL006196) (A.P. Ruhl, Y. Yang, H.C. Ackerman). This work was also funded in part by the National Cancer Institute (NCI) Intramural Research Program under contract HHSN26120080001E (C.A. Winkler), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Z01 DK04312 (J.B. Kopp), and the NHLBI grants K08HL12510 (R.P. Naik) and K08HL096841 (N.A. Zakai).
Publisher Copyright:
ß 2022 by the American Society of Nephrology
PY - 2022/1
Y1 - 2022/1
N2 - Background a-Globin is expressed in endothelial cells of resistance arteries, where it limits endothelial nitric oxide signaling and enhances a-adrenergic–mediated vasoconstriction. a-Globin gene (HBA) copy number is variable in people of African descent and other populations worldwide. Given the protective effect of nitric oxide in the kidney, we hypothesized that HBA copy number would be associated with kidney disease risk. Methods Community-dwelling Black Americans aged ≥45 years old were enrolled in a national longitudinal cohort from 2003 through 2007. HBA copy number was measured using droplet digital PCR. The prevalence ratio (PR) of CKD and the relative risk (RR) of incident reduced eGFR were calculated using modified Poisson multivariable regression. The hazard ratio (HR) of incident ESKD was calculated using Cox proportional hazards multivariable regression. Results Among 9908 participants, HBA copy number varied from 2 to 6. In analyses adjusted for demographic, clinical, and genetic risk factors, a one-copy increase in HBA was associated with 14% greater prevalence of CKD (PR, 1.14; 95% CI, 1.07 to 1.21; P<0.0001). While HBA copy number was not associated with incident reduced eGFR (RR, 1.06; 95% CI, 0.94 to 1.19; P50.38), the hazard of incident ESKD was 32% higher for each additional copy of HBA (HR, 1.32; 95% CI, 1.09 to 1.61; P50.005). Conclusions Increasing HBA copy number was associated with a greater prevalence of CKD and incidence of ESKD in a national longitudinal cohort of Black Americans.
AB - Background a-Globin is expressed in endothelial cells of resistance arteries, where it limits endothelial nitric oxide signaling and enhances a-adrenergic–mediated vasoconstriction. a-Globin gene (HBA) copy number is variable in people of African descent and other populations worldwide. Given the protective effect of nitric oxide in the kidney, we hypothesized that HBA copy number would be associated with kidney disease risk. Methods Community-dwelling Black Americans aged ≥45 years old were enrolled in a national longitudinal cohort from 2003 through 2007. HBA copy number was measured using droplet digital PCR. The prevalence ratio (PR) of CKD and the relative risk (RR) of incident reduced eGFR were calculated using modified Poisson multivariable regression. The hazard ratio (HR) of incident ESKD was calculated using Cox proportional hazards multivariable regression. Results Among 9908 participants, HBA copy number varied from 2 to 6. In analyses adjusted for demographic, clinical, and genetic risk factors, a one-copy increase in HBA was associated with 14% greater prevalence of CKD (PR, 1.14; 95% CI, 1.07 to 1.21; P<0.0001). While HBA copy number was not associated with incident reduced eGFR (RR, 1.06; 95% CI, 0.94 to 1.19; P50.38), the hazard of incident ESKD was 32% higher for each additional copy of HBA (HR, 1.32; 95% CI, 1.09 to 1.61; P50.005). Conclusions Increasing HBA copy number was associated with a greater prevalence of CKD and incidence of ESKD in a national longitudinal cohort of Black Americans.
UR - http://www.scopus.com/inward/record.url?scp=85123226655&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123226655&partnerID=8YFLogxK
U2 - 10.1681/ASN.2021050653
DO - 10.1681/ASN.2021050653
M3 - Article
C2 - 34706968
AN - SCOPUS:85123226655
SN - 1046-6673
VL - 33
SP - 213
EP - 224
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 1
ER -